Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Eltrombopag 25 mg tablets vs Revolade 25 mg tablets in healthy Thai volunteers under fasting conditions
TCTR20240925001Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eltrombopag (2 arms), sponsored by Bio-innova. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
eltrombopag
Beyond the preview
Go deeper on TCTR20240925001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240925001.